INS 518


Referencias correspondientes a la pieza INS 518 

1. Datos en archivo Laboratorios Bagó S.A.
2. Prospecto autorizado del producto Dioxaex B12 Laboratorios Bagó S.A.
3. Mauro G. L. Et al. Vitamin B12 in low back pain: a randomised, double-blind, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2000 May-Jun;4(3):53-8. 3. Kantor TG. Use of diclofenac in analgesia. Am J Med. 1986 Apr 28;80(4B):64-9.
4. Fassina, A.; Rubincci, A. et al. Muscular contracture as a component of low back pain: evaluation criteria and signicance of relaxant therapy. Int. Clin. Pharm. Res. 1986, Vol. VI Nro. 6, 501-507.
5. Todd, P.; Sorkin, E. Diclofenac Sodium: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efcacy. Drugs, Vol. 35, 244-285, 1988.
6. Data on file Laboratoios Bagó.
7. Maggi C.A., Lualdi P., Moutone G. Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man. European Journal of Clinical Pharmacology. February 1990, Volume 38, Issue 2, pp 207-208.
8. Escitalopram for the management of major depressive disorder: areview of its ecacy, safety, and patient acceptability. This article was published in the following Dove Press Journal: Patient Preferent and adherence. 3 December 2012.
9. Novo Humorap: Información para prescribir.
10. Van Marwijk H, Allick G, Wegman F, Bax A, Riphagen II. Alprazolamfor depression. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD007139. DOI: 0.1002/14651858.CD007139. pub2.
11. Julie Dopheide et al. The Psychopharmacology of Anxiety. Psychiatry Times. March 2002. Vol 19, Issue 3.
12. Tranquinal: Información para prescribir.
13. Rosembaum. J. The Development of Clonazepam as a Psychotropic: The Massachusets. General Hospital Experience. Clin. Psychiatry 2004, (suppl5) 3-6.
14. Jones Peter H y col. Efcacy and safety of ABT – 335 (fenobric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 201 (2009) 208-215.
15. Keech AC et al. FIELD study investigator. Effects of long-term fenobrate therapy on cardiovascular events in 9795people with type 2 diabetes mellitus (FIELD Study): randomised controlled trial. Lancet 2005;366:1849-61 .
16. Keech AC et al. FIELD study investigator. Effect of fenobrate on the need for laser treatment for diabetic retinophaty (FIELD Study): a randomized control trial. Lancet 2007;370:1687-97.
17. ACCORD Study Group. Effects of medical therapies on retinophaty progression in type 2 diabetes. N Engl. J Med 2010;363:233-44.
18. Burgess D, et al. Effects of fenobrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenobrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 2007;116:II_838 (abstract).
19. Nissen SE, Nicholls S, Sipahi I et al, Effect of very high – intensity statin therapy on regression of coronary atherosclerosis:The ASTEROID trial JAMA 2006;295(13):1556-1565.
20. De Vera MA, et al. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014 Oct;78(4):684-98.
21. Suppes T, Datto C, Minkwitz M, et al. Corridendum to “Eectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression” [J Aect Disord. 121(1-2)(2010)106-115]. J Aect Disord. 2014;168:485-493.
22. Seroquel XR: Información para prescribir.
23. Data on file, 3017412, AstraZeneca Pharmaceuticals LP.
24. Ateinhubl S et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randamized controlled trial, JAMA 202 Nov 20: 288 (19):2411-20.
25. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation analysis in a nationally representative managed-care population. Wiederkehr D. Berenson K, Casciano R, Stern L, Makenbaeva D, Mazoffari e, Lamerato L, Cobelli J, Curr Med Res Opin, 2009 Sep: 25(9):2317-25.
26. Kurtz TW, Gardner DG (1998) Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension 32:380-386.
27. Organization WH: De nition, diagnosis and classi cation of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis adnclassi cation of diabetes mellitus. Edited by: WHO. World Health Organization; 1999:1-28.
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
29. Data on le Laboratorios Bagó.
30. Prospecto autorizado del producto Lucidex XR.


El material incluido en este sitio ha sido concebido exclusivamente para los profesionales de la salud con fines informativos, y destinado a orientar sobre el uso adecuado de los medicamentos y a satisfacer sus necesidades de mayor información.

Todos los textos referidos a nuestros productos de venta bajo prescripción médica se corresponden a los lineamientos aprobados por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).

Laboratorios Bagó le sugiere consultar siempre a un profesional de la salud calificado ante cualquier duda sobre una condición médica particular.

He comprendido y deseo ver la información

Consultas médicas: